OBIO Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Orchestra Biomed Holdings Inc

Watchlist Manager

Watchlist

Price: 5.93 USD -4.66% Market Closed

Market Cap: $355.1m

O	Orchestra Biomed Holdings Inc NASDAQ:OBIO	US
	JPMorgan Chase & Co NYSE:JPM	US
C	CoreCivic Inc F:PSRA	US

Profitability Summary

Orchestra Biomed Holdings Inc's profitability score is 13/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

100%

Strong 3Y Average Gross Margin

94%

Gross Margin is Increasing

95% > 100%

Negative Operating Margin

-181%

Negative 3Y Average Operating Margin

-1 776%

Operating Margin is Increasing

-1 023% > -181%

Negative Net Margin

-186%

Negative 3Y Average Net Margin

-1 699%

Net Margin is Increasing

-991% > -186%

Negative Free Cash Flow Margin

-185%

Negative 3Y Average Free Cash Flow Margin

-1 456%

Free Cash Flow Margin is Increasing

-950% > -185%

Negative ROE

-401%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-2 078%

Declining ROIC

-822% > -3 627%

View All

Hide

Collapse

13 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.